Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
What happens after fingolimod discontinuation? A multicentre real-life experience.
Landi D, Signori A, Cellerino M, Fenu G, Nicoletti CG, Ponzano M, Mancuso E, Fronza M, Ricchiuto ME, Boffa G, Inglese M, Marfia GA, Cocco E, Frau J. Landi D, et al. Among authors: boffa g. J Neurol. 2022 Feb;269(2):796-804. doi: 10.1007/s00415-021-10658-8. Epub 2021 Jun 16. J Neurol. 2022. PMID: 34136943
Different MRI patterns in MS worsening after stopping fingolimod.
Lapucci C, Baroncini D, Cellerino M, Boffa G, Callegari I, Pardini M, Novi G, Sormani MP, Mancardi GL, Ghezzi A, Zaffaroni M, Uccelli A, Inglese M, Roccatagliata L. Lapucci C, et al. Among authors: boffa g. Neurol Neuroimmunol Neuroinflamm. 2019 Apr 16;6(4):e566. doi: 10.1212/NXI.0000000000000566. eCollection 2019 Jul. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31086807 Free PMC article.
Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS.
Cellerino M, Cordano C, Boffa G, Bommarito G, Petracca M, Sbragia E, Novi G, Lapucci C, Capello E, Uccelli A, Inglese M. Cellerino M, et al. Among authors: boffa g. Neurol Neuroimmunol Neuroinflamm. 2019 Aug 12;6(5):e596. doi: 10.1212/NXI.0000000000000596. Print 2019 Sep. Neurol Neuroimmunol Neuroinflamm. 2019. PMID: 31454778 Free PMC article.
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience.
Zecca C, Bovis F, Novi G, Capobianco M, Lanzillo R, Frau J, Repice AM, Hakiki B, Realmuto S, Bonavita S, Curti E, Brambilla L, Mataluni G, Cavalla P, Di Sapio A, Signoriello E, Barone S, Maniscalco GT, Maietta I, Maraffi I, Boffa G, Malucchi S, Nozzolillo A, Coghe G, Mechi C, Salemi G, Gallo A, Sacco R, Cellerino M, Malentacchi M, De Angelis M, Lorefice L, Magnani E, Prestipino E, Sperli F, Brescia Morra V, Fenu G, Barilaro A, Abbadessa G, Signori A, Granella F, Amato MP, Uccelli A, Gobbi C, Sormani MP. Zecca C, et al. Among authors: boffa g. Mult Scler. 2020 Oct;26(12):1519-1531. doi: 10.1177/1352458519872889. Epub 2019 Oct 1. Mult Scler. 2020. PMID: 31573386
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study.
Cellerino M, Ivaldi F, Pardini M, Rotta G, Vila G, Bäcker-Koduah P, Berge T, Laroni A, Lapucci C, Novi G, Boffa G, Sbragia E, Palmeri S, Asseyer S, Høgestøl E, Campi C, Piana M, Inglese M, Paul F, Harbo HF, Villoslada P, Kerlero de Rosbo N, Uccelli A. Cellerino M, et al. Among authors: boffa g. Neurol Neuroimmunol Neuroinflamm. 2020 Mar 5;7(3):e693. doi: 10.1212/NXI.0000000000000693. Print 2020 May. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32139439 Free PMC article.
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab.
Boffa G, Lapucci C, Sbragia E, Varaldo R, Raiola AM, Currò D, Roccatagliata L, Capello E, Laroni A, Mikulska M, Gualandi F, Uccelli A, Angelucci E, Mancardi GL, Inglese M. Boffa G, et al. Eur J Neurol. 2020 Oct;27(10):2047-2055. doi: 10.1111/ene.14324. Epub 2020 Jun 16. Eur J Neurol. 2020. PMID: 32418281
263 results